查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612744

癌症幹細胞市場：按類型、來源、癌症類型、應用、最終用戶分類 - 2025-2030 年全球預測

Cancer Stem Cells Market by Type (Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell), Source (Allogenic, Autologous), Cancer Type, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症幹細胞市場價值為47.2億美元，預計到2024年將達到52.1億美元，複合年成長率為10.55%，到2030年將達到95.4億美元。

癌症幹細胞（CSC）是癌細胞的一個亞群，能夠自我更新並分化成腫瘤中發現的各種細胞類型。 CSC在癌症增殖、轉移和復發中發揮重要作用，並且在癌症研究和治療開發中變得越來越重要。對 CSCs 研究的需求有可能透過靶向有助於抗藥性和腫瘤異質性的細胞來徹底改變癌症治療。 CSC 研究的應用範圍從藥物開發到個人化醫療，旨在提高現有癌症治療的有效性並降低復發率。最終用途範圍包括許多生物技術公司、製藥公司和專注於腫瘤學的學術研究機構。

主要市場統計
基準年[2023] 47.2億美元
預測年份 [2024] 52.1億美元
預測年份 [2030] 95.4億美元
複合年成長率（%） 10.55%

CSC 研究市場是由癌症發病率上升、幹細胞研究技術進步以及對個人化醫療日益成長的興趣所推動的。商業機會存在於開發用於 CSC 識別的新型生物標記和特異性中和 CSC 而不損害正常細胞的標靶治療。大力投資癌症研究的政府和私人組織提供了進一步的合作和資金籌措機會。然而，由於高昂的研究成本、監管障礙和倫理問題，特別是在幹細胞的使用方面，市場成長面臨挑戰。對CSC相對淺薄的生物學認知也是一個主要限制，阻礙了有效治療方法的發現和發展。

在創新和研究方面，探索CSC的遺傳和表觀遺傳景觀可能會揭示新的治療標靶。開發選擇性靶向這些細胞的無毒 CSC 抑制劑和基於免疫的治療方法是一個有前途的領域。另一個創新領域是利用人工智慧來預測 CSC 行為和治療反應，這有可能顯著增強藥物開發過程。市場的本質是動態的，快速的科學進步創造了一個高度競爭的環境。能夠利用尖端研究提供有效、個人化癌症治療的公司將獲得顯著的競爭優勢。

市場動態：揭示快速發展的癌症幹細胞市場的關鍵市場洞察

供需的動態交互作用正在改變癌症幹細胞市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全世界對癌症的認知不斷增強以及對有效治療方法的需求
    • 政府對幹細胞研究的支持政策和獎勵
  • 市場限制因素
    • 幹細胞研究的嚴格監管框架
  • 市場機會
    • 癌症研究的基因組定序與生物技術創新
    • 學術機構和生物製藥公司之間加強幹細胞研究合作
  • 市場挑戰
    • 癌症幹細胞的複雜性與幹細胞異質性和可塑性有關

波特五力策略工具引領癌症幹細胞市場

波特的五力框架是了解癌症幹細胞市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症幹細胞市場的影響

外部宏觀環境因素在塑造癌症幹細胞市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症幹細胞市場的競爭格局

癌症幹細胞市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症幹細胞市場供應商的績效評估

FPNV定位矩陣是評估癌症幹細胞市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製癌症幹細胞市場的成功之路

癌症幹細胞市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地對癌症的認知不斷提高，對有效治療方法的需求也增加。
      • 支持幹細胞研究的政府政策和獎勵
    • 抑制因素
      • 幹細胞研究的嚴格法規結構
    • 機會
      • 癌症研究的基因組定序與生物技術創新
      • 加強學術機構與生物製藥公司在幹細胞研究的合作
    • 任務
      • 與癌症幹細胞異質性和可塑性相關的複雜性
  • 市場區隔分析
    • 類型：在癌症生物學中使用人類 ES 細胞來了解癌症機制並支持標靶癌症治療方法的開發
    • 癌症類型：癌症幹細胞擴大用於需要有效治療和治療的各種癌症診斷
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症幹細胞市場：依類型

  • 成體幹細胞
  • 人類胚胎幹細胞
  • 誘導性多功能細胞

第7章癌症幹細胞市場：依來源分類

  • 同種異體的
  • 自體移植

第 8 章按癌症類型分類的癌症幹細胞市場

  • 乳癌
  • 肺癌
  • 攝護腺癌

第9章癌症幹細胞市場：依應用分類

  • 臨床調查
  • 藥物開發
  • 標靶治療

第 10 章癌症幹細胞市場：依最終用戶分類

  • 學術研究所
  • 醫院和細胞庫
  • 製藥和生物技術公司

第11章美洲癌症幹細胞市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區癌症幹細胞市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的癌症幹細胞市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • StemCell Technologies 透過收購 Propagenix 來加強產品組合，並開始推動癌症幹細胞研究
    • Astra Zeneca透過收購 Graycell Biotechnologies 增強細胞治療能力
    • Max Healthcare 與Immunoact 合作推出先進的 CAR-T 細胞療法
  • 戰略分析和建議

公司名單

  • AcceGen
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Biorestorative Therapies Inc.
  • BrainStorm Cell Limited
  • Gamida Cell Ltd.
  • GenScript Biotech Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • Qiagen NV
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Takara Bio Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-99555D550527

The Cancer Stem Cells Market was valued at USD 4.72 billion in 2023, expected to reach USD 5.21 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 9.54 billion by 2030.

Cancer Stem Cells (CSCs) are a subpopulation of cancer cells possessing the ability to self-renew and differentiate into various cell types found in tumors. They play a crucial role in cancer proliferation, metastasis, and recurrence, which elevates their importance in cancer research and therapy development. The necessity of CSCs research lies in their potential to revolutionize cancer treatment by targeting cells that contribute to drug resistance and tumor heterogeneity. Applications of CSC research span from drug development to personalized medicine, aiming to enhance the efficacy of existing cancer treatments and reduce relapse rates. The end-use scope prominently includes biotechnology firms, pharmaceutical companies, and academic research institutions focused on oncology.

KEY MARKET STATISTICS
Base Year [2023] USD 4.72 billion
Estimated Year [2024] USD 5.21 billion
Forecast Year [2030] USD 9.54 billion
CAGR (%) 10.55%

The market for CSC research is driven by increasing cancer prevalence, technological advancements in stem cell research, and growing interest in personalized medicine. Opportunities exist in the development of novel biomarkers for CSC identification and targeted therapeutics that specifically neutralize CSCs without harming normal cells. Governments and private entities investing heavily in cancer research present additional opportunities for collaborations and funding. However, market growth faces challenges due to high research costs, regulatory hurdles, and ethical concerns, particularly concerning stem cell usage. A significant limitation is the relatively nascent understanding of CSC biology, which can impede the discovery and development of effective therapies.

In terms of innovation and research, exploring the genetic and epigenetic landscapes of CSCs could unveil new therapeutic targets. Developing non-toxic CSC inhibitors or immune-based therapies to selectively target these cells is a promising area. Another innovative field is the utilization of artificial intelligence to predict CSC behavior and treatment responses, which could significantly enhance drug development processes. The nature of the market is dynamic, with rapid scientific advancements creating a highly competitive environment. Companies that can leverage cutting-edge research to offer effective, personalized cancer treatments are positioned to gain a significant competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Stem Cells Market

The Cancer Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness of cancer worldwide and the need for effective therapeutic options
    • Supportive government policies and incentives for stem cell research
  • Market Restraints
    • Stringent regulatory frameworks for stem cell research
  • Market Opportunities
    • Innovations in genomics sequencing and biotechnology for cancer research
    • Increased collaboration between academic institutions and biopharmaceutical companies for stem cell research
  • Market Challenges
    • Complexities associated with the heterogeneity and plasticity of cancer stem cells

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Stem Cells Market

A detailed market share analysis in the Cancer Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Stem Cells Market

A strategic analysis of the Cancer Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AcceGen, Becton, Dickinson and Company, Bio-Techne Corporation, Biorestorative Therapies Inc., BrainStorm Cell Limited, Gamida Cell Ltd., GenScript Biotech Corporation, JCR Pharmaceuticals Co., Ltd., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novartis AG, Qiagen N.V, Sartorius AG, STEMCELL Technologies Canada Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem Cell.
  • Based on Source, market is studied across Allogenic and Autologous.
  • Based on Cancer Type, market is studied across Breast Cancer, Lung Cancer, and Prostate Cancer.
  • Based on Application, market is studied across Clinical Research, Drug Development, and Targeted Therapy.
  • Based on End-User, market is studied across Academic & Research Institutes, Hospitals & Cell Banks, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness of cancer worldwide and the need for effective therapeutic options
      • 5.1.1.2. Supportive government policies and incentives for stem cell research
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory frameworks for stem cell research
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in genomics sequencing and biotechnology for cancer research
      • 5.1.3.2. Increased collaboration between academic institutions and biopharmaceutical companies for stem cell research
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the heterogeneity and plasticity of cancer stem cells
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Utilization of hESCs in cancer biology to understand cancer mechanisms and support the development of targeted cancer therapies
    • 5.2.2. Cancer Type: Increasing usage of cancer stem cells in varied cancer diagnoses to necessitates effective treatments and therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Adult Stem Cell
  • 6.3. Human Embryonic Stem Cell
  • 6.4. Induced Pluripotent Stem Cell

7. Cancer Stem Cells Market, by Source

  • 7.1. Introduction
  • 7.2. Allogenic
  • 7.3. Autologous

8. Cancer Stem Cells Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Lung Cancer
  • 8.4. Prostate Cancer

9. Cancer Stem Cells Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Research
  • 9.3. Drug Development
  • 9.4. Targeted Therapy

10. Cancer Stem Cells Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Hospitals & Cell Banks
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Cancer Stem Cells Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Stem Cells Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Stem Cells Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. StemCell Technologies Enhances Portfolio with Propagenix Acquisition to Advance Cancer Stem Cell Research
    • 14.3.2. AstraZeneca Enhances Cell Therapy Capabilities with Gracell Biotechnologies Acquisition
    • 14.3.3. Max Healthcare Initiates Advanced CAR-T Cell Therapy in Partnership with ImmunoACT
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AcceGen
  • 2. Becton, Dickinson and Company
  • 3. Bio-Techne Corporation
  • 4. Biorestorative Therapies Inc.
  • 5. BrainStorm Cell Limited
  • 6. Gamida Cell Ltd.
  • 7. GenScript Biotech Corporation
  • 8. JCR Pharmaceuticals Co., Ltd.
  • 9. Lonza Group Ltd.
  • 10. Merck KGaA
  • 11. Miltenyi Biotec B.V. & Co. KG
  • 12. Novartis AG
  • 13. Qiagen N.V
  • 14. Sartorius AG
  • 15. STEMCELL Technologies Canada Inc.
  • 16. Takara Bio Inc.
  • 17. Takeda Pharmaceutical Company Limited
  • 18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CANCER STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CANCER STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ADULT STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER STEM CELLS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER STEM CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER STEM CELLS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER STEM CELLS MARKET SIZE, BY HOSPITALS & CELL BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER STEM CELLS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. CANCER STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. CANCER STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023